Table 2.
Baseline characteristics of the patients who developed Pneumocystis pneumonia a
| Patient | Biologic | Age (years) | Sex | RA duration (months) b | Treatment duration (months) c | Pulmonary disease | DM | DAS28 score (ESR) | PSL (mg) | KL-6 (U/ml) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
IFX |
71 |
Female |
72 |
10 |
(-) |
(-) |
6.24 |
2.5 |
ND |
| 2 |
IFX |
78 |
Female |
79 |
1 |
(+) |
(-) |
6.99 |
1.0 |
178 |
| 3 |
IFX |
62 |
Male |
21 |
20 |
(+) |
(-) |
7.40 |
2.0 |
893 |
| 4 |
IFX |
78 |
Female |
40 |
1 |
(+) |
(-) |
8.04 |
8.0 |
398 |
| 5 |
IFX |
57 |
Male |
5 |
2 |
(+) |
(-) |
3.38 |
0 |
304 |
| 6 |
ETN |
73 |
Male |
2 |
3 |
(+) |
(-) |
7.20 |
50 |
366 |
| 7 |
ETN |
59 |
Female |
252 |
15 |
(-) |
(-) |
5.60 |
1.0 |
224 |
| 8 |
ETN |
75 |
Male |
132 |
5 |
(+) |
(-) |
6.75 |
5.0 |
624 |
| 9 |
TCZ |
73 |
Male |
84 |
8 |
(+) |
(-) |
7.00 |
10 |
445 |
| Mean | 69.5 | 76.3 | 7.2 | 7/9 | 0/9 | 6.51 | 8.83 | 429 |
aPCP developed in nine patients who did receive trimethoprim/sulfamethoxazole prophylaxis. Eight of nine patients were given glucocorticoids. -: Without DM; +: With DM; DAS28: Disease Activity Score in 28 joints; DM: Diabetes mellitus; ESR: Erythrocyte sedimentation rate; ETN: Etanercept; IFX: Infliximab; PCP: Pneumocystis pneumonia; PSL: Prednisolone; RA: Rheumatoid arthritis; TCZ: Tocilizumab. bRA duration was measured between the onset of RA and the initiation of biologics. cTreatment duration was measured between the initiation of biologics and PCP development.